
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio is positioned for success with their strong focus on genetic medicines, cutting-edge technology, and a promising pipeline led by their lead candidate PBFT02. They have a strong financial outlook with a conservative approach, reflected in their target price of $23 per share based on a sum-of-the-parts peak revenue analysis and a 12% discount rate.
Bears say
Passage Bio is a clinical-stage genetic medicines company focused on developing one-time gene therapies for neurodegenerative diseases, which poses typical upsides and downsides for a biotech company. Recently, the company faced safety issues and had to amend protocols for its lead programs, and competition in the industry may further delay trials or impact commercial potential. With cash overhang and potentially limited access to future financing, Passage Bio faces significant risks in progressing their pipeline and achieving regulatory approvals.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares